Latest News
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Latest News
Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body
CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...
Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease
The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...
AI-Discovered Drugs in 2026: The State of Play
Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...
Why Ingredient Research Is Only the Beginning of a Health Product
I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
Featured Articles
Further News
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
Expansion at Oxford Science Park Boosts Innovation Ecosystem
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
Remote Stroke Surgery Breakthrough with New Robotic System
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Bacterial Movement Beyond Flagella: Surprising New Mechanisms Uncovered
Emerging Evidence of Alternative Motility For decades, scientists have believed that bacterial movement relied almost entirely on the rotation of whip-like flagella, which propel cells through liquids or across surfaces. However, new research has revealed that some...
The Passing of a Scientific Giant: James D. Watson
Renowned molecular biologist James D. Watson has died at the age of 97, his son and the Cold Spring Harbor Laboratory (CSHL) in New York confirmed. The scientist, best known for co-discovering the double helix structure of DNA in 1953, passed away following a brief...
The Rise of Cell and Gene Therapy Hubs Across Northern England
The life sciences landscape in northern England is undergoing a dynamic evolution, driven by the growing importance of advanced therapies such as cell and gene treatments. These innovative approaches, which aim to treat or cure diseases by intervening at the level of...
Current Talent, Skills and Infrastructure in the Life Science Industry
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
Rewriting the MND Playbook
How AI and Biomarkers Are Accelerating the Fight Against Motor Neurone Disease Every ninety minutes in the United Kingdom, someone receives a diagnosis of Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), and every ninety minutes, someone...
Challenges in Life Sciences Real Estate
The commercial real estate market serving the life sciences industry is currently undergoing a complex period of adjustment. The underlying dynamics that once propelled rapid growth, such as enthusiastic venture capital, strong demand from biotech and pharmaceutical...
Age Related T Cell Changes Weaken Vaccine Response in Older People
As the population ages, one of the major challenges facing public health is that vaccines tend to become less effective in older adults. A growing body of research increasingly points to specific changes in T cells, critical components of the immune system, as a key...
First Malaria Treatment Approved for Babies and Young Children
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.